mometasone furoate; olopatadine hydrochloride · Glenmark Speclt · NDA 211746
Ryaltris
Earliest generic entry, as listed
21 Nov 2044
Blocked by patent: US 12653833.
Listed patents · 17 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 12653833 | product, use U-4564 | 21 Nov 2044 |
| US 12303635 | substance, product | 8 Apr 2039 |
| US 11679210 | product | 3 Sep 2038 |
| US 10016443 | use U-3297 | 4 Sep 2034 |
| US 10376526 | product | 4 Sep 2034 |
| US 10517880 | product, use U-3297 | 4 Sep 2034 |
| US 10548907 | use U-3297 | 4 Sep 2034 |
| US 10561672 | product | 4 Sep 2034 |
| US 10646500 | use U-3297 | 4 Sep 2034 |
| US 10758550 | use U-3296 | 4 Sep 2034 |
| US 10765686 | use U-3295 | 4 Sep 2034 |
| US 11400101 | use U-3297 | 4 Sep 2034 |
| US 12064442 | use U-3297 | 4 Sep 2034 |
| US 9078923 | product, use U-3297 | 4 Sep 2034 |
| US 9370483 | product | 4 Sep 2034 |
| US 9750754 | product, use U-3297 | 4 Sep 2034 |
| US 9937189 | product | 4 Sep 2034 |
Exclusivities · 1 unexpired
| NPP | new patient population | 7 Jul 2029 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 211746 · 001 · RLD | spray, metered, nasal | 0.025MG/SPRAY;0.665MG/SPRAY | 21 Nov 2044 |